Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day.
Related Products:
Thymopentin; Leupeptin hemisulfate; Etelcalcetide; Emideltide; Lixisenatide; Aprotinin; GHRP-6; GHRP-2; Liraglutide